
Respiratory Disease Vaccine Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
Description
The Global Respiratory Disease Vaccine Market was valued at USD 24.7 billion in 2023 and is projected to grow at a CAGR of 7.7% from 2024 to 2032. The increasing prevalence of respiratory illnesses, including asthma, COPD, and influenza, has driven demand for preventive solutions such as vaccines. Rising global awareness of respiratory health, especially after the recent pandemic, has pushed governments and healthcare organizations to prioritize immunization efforts. With a growing emphasis on disease prevention, the market is expected to expand significantly as vaccination programs gain traction worldwide.
A respiratory disease vaccine helps protect against infections affecting the lungs and airways by stimulating the body's immune system to recognize and combat specific pathogens. Technological advancements in vaccine development have played a key role in market expansion. The viral vector segment, which generated around USD 15.8 billion in revenue in 2023, has dominated the market due to its ability to enable rapid vaccine development. Enhanced vector engineering techniques have improved vaccine safety and effectiveness, strengthening the segment's position.
Based on age group, the market is divided into pediatric and adult categories, with the adult segment expected to exceed USD 40.3 billion by 2032. Adults are more susceptible to severe respiratory infections, contributing significantly to disease transmission. Widespread adult immunization efforts help curb infection rates, making this segment the fastest-growing in the market.
In terms of infection type, the market is segmented into COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, and other infections. The COVID-19 segment accounted for USD 3.2 billion in 2023 due to the high transmissibility of the virus and its severe health implications. Governments and healthcare systems prioritized vaccination efforts to curb the spread, which contributed to the market dominance of this segment. Public awareness of the importance of COVID-19 immunization further supported the high demand for these vaccines.
Distribution channels for respiratory disease vaccines include hospital pharmacies, retail pharmacies, and other channels. The hospital pharmacy segment is poised to grow at a CAGR of 7.8% through 2032. These facilities serve as key vaccination centers, providing convenient access to immunization services. Retail pharmacies also play a crucial role, offering vaccines without requiring prior appointments. Government programs often collaborate with these distribution channels to ensure widespread vaccine availability, further strengthening the segment’s dominance.
Regionally, North America led the market with a revenue of USD 10.7 billion in 2023 and is anticipated to experience steady growth. A strong healthcare infrastructure, high healthcare spending, and increasing public awareness about immunization have propelled market expansion. Continuous investment in research and development, along with educational initiatives by healthcare authorities, has further driven vaccine adoption in the region.
A respiratory disease vaccine helps protect against infections affecting the lungs and airways by stimulating the body's immune system to recognize and combat specific pathogens. Technological advancements in vaccine development have played a key role in market expansion. The viral vector segment, which generated around USD 15.8 billion in revenue in 2023, has dominated the market due to its ability to enable rapid vaccine development. Enhanced vector engineering techniques have improved vaccine safety and effectiveness, strengthening the segment's position.
Based on age group, the market is divided into pediatric and adult categories, with the adult segment expected to exceed USD 40.3 billion by 2032. Adults are more susceptible to severe respiratory infections, contributing significantly to disease transmission. Widespread adult immunization efforts help curb infection rates, making this segment the fastest-growing in the market.
In terms of infection type, the market is segmented into COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, and other infections. The COVID-19 segment accounted for USD 3.2 billion in 2023 due to the high transmissibility of the virus and its severe health implications. Governments and healthcare systems prioritized vaccination efforts to curb the spread, which contributed to the market dominance of this segment. Public awareness of the importance of COVID-19 immunization further supported the high demand for these vaccines.
Distribution channels for respiratory disease vaccines include hospital pharmacies, retail pharmacies, and other channels. The hospital pharmacy segment is poised to grow at a CAGR of 7.8% through 2032. These facilities serve as key vaccination centers, providing convenient access to immunization services. Retail pharmacies also play a crucial role, offering vaccines without requiring prior appointments. Government programs often collaborate with these distribution channels to ensure widespread vaccine availability, further strengthening the segment’s dominance.
Regionally, North America led the market with a revenue of USD 10.7 billion in 2023 and is anticipated to experience steady growth. A strong healthcare infrastructure, high healthcare spending, and increasing public awareness about immunization have propelled market expansion. Continuous investment in research and development, along with educational initiatives by healthcare authorities, has further driven vaccine adoption in the region.
Table of Contents
119 Pages
- Chapter 1 Methodology
- 1.1 Market segmentation
- 1.2 Market definitions
- 1.3 Research design
- 1.4 Market size estimates and calculations
- 1.4.1 Approach 1: Revenue share analysis (Global Market analysis)
- 1.4.2 Approach 2 - Base year calculation
- 1.4.3 Approach 3: Investor presentations
- 1.4.4 Key trends for market estimates
- 1.5 Forecast model
- 1.6 Primary research & validation
- 1.6.1 Primary sources
- 1.6.2 Data mining sources
- 1.6.2.1 Paid sources
- 1.6.2.2 Public sources
- Chapter 2 Executive Summary
- 2.1 Global market 360° synopsis, 2021- 2032 (USD Billion)
- 2.1.1 Business trends
- 2.1.2 Technology trends
- 2.1.3 Age Group trends
- 2.1.4 Infection trends
- 2.1.5 Distribution Channel trends
- 2.1.6 Regional trends
- Chapter 3 Respiratory Disease Vaccine Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of respiratory diseases
- 3.2.1.2 Increasing focus on preventive healthcare
- 3.2.1.3 Rising technological advancements
- 3.2.1.4 Growing healthcare expenditure
- 3.2.2 Restraints
- 3.3 Growth potential analysis
- 3.3.1 By technology
- 3.3.2 By age group
- 3.3.3 By infection
- 3.3.4 By distribution channel
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Global mRNA Vaccines market estimates and forecast, 2021 - 2032 ($ Mn)
- 3.7.1 U.S. mRNA Vaccines market estimates and forecast, by application, 2021 - 2032 ($ Mn)
- 3.7.2 Europe mRNA Vaccines market estimates and forecast, by application, 2021 - 2032 ($ Mn)
- 3.7.3 Japan mRNA Vaccines market estimates and forecast, by application, 2021 - 2032 ($ Mn)
- 3.7.4 Rest of World mRNA Vaccines market estimates and forecast, by application, 2021 - 2032 ($ Mn)
- 3.8 Gap analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
- Chapter 4 Competitive Landscape
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
- Chapter 5 Respiratory Disease Vaccine Market, By Technology
- 5.1 Conjugate
- 5.2 Recombinant
- 5.3 Inactivated
- 5.4 Viral vector
- 5.5 Live attenuated
- 5.6 Other technologies
- Chapter 6 Respiratory Disease Vaccine Market, By Age Group
- 6.1 Adult
- 6.2 Pediatric
- Chapter 7 Respiratory Disease Vaccine Market, By Infection
- 7.1 COVID-19
- 7.2 Pneumonia
- 7.3 Influenza
- 7.4 Respiratory Syncytial Virus (RSV)
- 7.5 Other infections
- Chapter 8 Respiratory Disease Vaccine Market, By Distribution Channel
- 8.1 Hospital pharmacies
- 8.2 Retail pharmacies
- 8.3 Other distribution channels
- Chapter 9 Respiratory Disease Vaccine Market, By Region
- 9.1 North America
- 9.2 Europe
- 9.3 Asia Pacific
- 9.4 Latin America
- 9.5 MEA 84
- Chapter 10 Company Profile
- 10.1 AstraZeneca plc
- 10.1.1 Global overview
- 10.1.2 Business overview
- 10.1.3 Financial data
- 10.1.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.1.4 Product landscape
- 10.1.5 Strategic outlook
- 10.1.6 SWOT analysis
- 10.2 GlaxoSmithKline plc
- 10.2.1 Global overview
- 10.2.2 Business overview
- 10.2.3 Financial data
- 10.2.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.2.4 Product landscape
- 10.2.5 Strategic outlook
- 10.2.1 SWOT analysis
- 10.3 Johnson & Johnson
- 10.3.1 Global overview
- 10.3.2 Business overview
- 10.3.3 Financial data
- 10.3.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.3.4 Product landscape
- 10.3.5 Strategic outlook
- 10.3.6 SWOT analysis
- 10.4 Merck & Co., Inc
- 10.4.1 Global overview
- 10.4.2 Business overview
- 10.4.3 Financial data
- 10.4.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
- 10.4.4 Product landscape
- 10.4.5 Strategic outlook
- 10.4.6 SWOT analysis
- 10.5 Moderna, Inc.
- 10.5.1 Global overview
- 10.5.2 Business overview
- 10.5.3 Financial data
- 10.5.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.5.4 Product landscape
- 10.5.5 Strategic outlook
- 10.5.6 SWOT analysis
- 10.6 Novavax, Inc.
- 10.6.1 Global overview
- 10.6.2 Business overview
- 10.6.3 Financial data
- 10.6.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.6.4 Product landscape
- 10.6.5 Strategic outlook
- 10.6.6 SWOT analysis
- 10.7 Pfizer Inc.
- 10.7.1 Global overview
- 10.7.2 Business overview
- 10.7.3 Financial data
- 10.7.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.7.4 Product landscape
- 10.7.5 Strategic outlook
- 10.7.6 SWOT analysis
- 10.8 Sanofi
- 10.8.1 Global overview
- 10.8.2 Business overview
- 10.8.3 Financial data
- 10.8.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.8.4 Product landscape
- 10.8.5 Strategic outlook
- 10.8.6 SWOT analysis
- 10.9 Serum Institute of India Pvt. Ltd.
- 10.9.1 Global overview
- 10.9.2 Business overview
- 10.9.3 Financial data
- 10.9.4 Product landscape
- 10.9.5 Strategic outlook
- 10.9.6 SWOT analysis
- 10.10 Sinovac Biotech Ltd.
- 10.10.1 Global overview
- 10.10.2 Business overview
- 10.10.3 Financial data
- 10.10.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.10.4 Product landscape
- 10.10.5 Strategic outlook
- 10.10.6 SWOT analysis
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.